Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(7):862–869. doi: 10.1038/bjc.1997.476

Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).

J Hofmann 1, I Utz 1, M Spitaler 1, S Hofer 1, M Rybczynska 1, W T Beck 1, D B Herrmann 1, H Grunicke 1
PMCID: PMC2228059  PMID: 9328144

Abstract

The thioether phospholipid ilmofosine (BM 41 440) is a new anti-cancer drug presently undergoing phase II clinical trials. Because resistance to anti-tumour drugs is a major problem in cancer treatment, we investigated the resistance of different cell lines to this compound. Here we report that the multidrug-resistant cell lines MCF7/ADR, CCRFNCR1000, CCRF/ADR500, CEM/VLB100 and HeLa cell lines transfected with a wild-type and mutated (gly/val185) multidrug resistance 1 gene (MDR1) are cross-resistant to ilmofosine compared with the sensitive parental cell lines. In CEMNM-1 cells, in which the resistance is associated with an altered topoisomerase II gene, no cross-resistance to ilmofosine was observed. Ilmofosine is not capable of modulating multidrug resistance and neither does it reduce the labelling of the P-glycoprotein (P-gp) by azidopine nor alter ATPase activity significantly. The resistance to ilmofosine in multidrug-resistant CCRF/VCR1000 cells cannot be reversed by the potent multidrug resistance modifier dexniguldipine-HCI (B8509-035). A tenfold excess of ilmofosine does not prevent the MDR-modulating effect of dexniguldipine-HCl. Treatment of cells with ilmofosine does not alter the levels of MDR1 mRNA. Long-term treatment of an ilmofosine-resistant Meth A subline with the drug does not induce multidrug resistance, indicating that ilmofosine does not increase the level of P-gp. Determination of the MDR2 mRNA levels in the cells revealed that the resistance pattern to ilmofosine is not correlated with the expression of this gene. It is concluded, therefore, that multidrug-resistant cells are cross-resistant to ilmofosine and that the compound is not a substrate of Pgp. No association between the expression of the MDR2-encoded P-gp and resistance to ilmofosine was observed. It is supposed that MDR1-associated alterations in membrane lipids cause resistance to ilmofosine.

Full text

PDF
862

Images in this article

865Figure 4
on p.865
866Figure 8
on p.866
867Figure 9
on p.867

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad S., Glazer R. I. Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol. 1993 Jun;43(6):858–862. [PubMed] [Google Scholar]
  2. Beck W. T., Mueller T. J., Tanzer L. R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 1979 Jun;39(6 Pt 1):2070–2076. [PubMed] [Google Scholar]
  3. Berdel W. E. Membrane-interactive lipids as experimental anticancer drugs. Br J Cancer. 1991 Aug;64(2):208–211. doi: 10.1038/bjc.1991.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chambers T. C., Zheng B., Kuo J. F. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol. 1992 Jun;41(6):1008–1015. [PubMed] [Google Scholar]
  5. Chaudhary P. M., Roninson I. B. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res. 1992;4(7):281–290. [PubMed] [Google Scholar]
  6. Danks M. K., Schmidt C. A., Cirtain M. C., Suttle D. P., Beck W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 1988 Nov 29;27(24):8861–8869. doi: 10.1021/bi00424a026. [DOI] [PubMed] [Google Scholar]
  7. Doige C. A., Yu X., Sharom F. J. ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta. 1992 Aug 24;1109(2):149–160. doi: 10.1016/0005-2736(92)90078-z. [DOI] [PubMed] [Google Scholar]
  8. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–171. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  9. Fleer E. A., Berkovic D., Eibl H., Unger C. Investigations on the cellular uptake of hexadecylphosphocholine. Lipids. 1993 Aug;28(8):731–736. doi: 10.1007/BF02535995. [DOI] [PubMed] [Google Scholar]
  10. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  11. Hamada H., Tsuruo T. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase. J Biol Chem. 1988 Jan 25;263(3):1454–1458. [PubMed] [Google Scholar]
  12. Herrmann D. B. Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl lysophospholipid analogues. J Natl Cancer Inst. 1985 Sep;75(3):423–430. [PubMed] [Google Scholar]
  13. Himmelmann A. W., Danhauser-Riedl S., Steinhauser G., Busch R., Modest E. J., Noseda A., Rastetter J., Vogler W. R., Berdel W. E. Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro. Cancer Chemother Pharmacol. 1990;26(6):437–443. doi: 10.1007/BF02994095. [DOI] [PubMed] [Google Scholar]
  14. Hofmann J., O'Connor P. M., Jackman J., Schubert C., Ueberall F., Kohn K. W., Grunicke H. The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochem Biophys Res Commun. 1994 Mar 15;199(2):937–943. doi: 10.1006/bbrc.1994.1319. [DOI] [PubMed] [Google Scholar]
  15. Hofmann J., Ueberall F., Posch L., Maly K., Herrmann D. B., Grunicke H. Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids. 1989 Apr;24(4):312–317. doi: 10.1007/BF02535169. [DOI] [PubMed] [Google Scholar]
  16. Hofmann J., Wolf A., Spitaler M., Böck G., Drach J., Ludescher C., Grunicke H. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol. 1992;118(5):361–366. doi: 10.1007/BF01294440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kane S. E., Reinhard D. H., Fordis C. M., Pastan I., Gottesman M. M. A new vector using the human multidrug resistance gene as a selectable marker enables overexpression of foreign genes in eukaryotic cells. Gene. 1989 Dec 14;84(2):439–446. doi: 10.1016/0378-1119(89)90518-0. [DOI] [PubMed] [Google Scholar]
  18. Kimmig A., Gekeler V., Neumann M., Frese G., Handgretinger R., Kardos G., Diddens H., Niethammer D. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res. 1990 Nov 1;50(21):6793–6799. [PubMed] [Google Scholar]
  19. Lavie Y., Cao H., Bursten S. L., Giuliano A. E., Cabot M. C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem. 1996 Aug 9;271(32):19530–19536. doi: 10.1074/jbc.271.32.19530. [DOI] [PubMed] [Google Scholar]
  20. Le Moyec L., Tatoud R., Degeorges A., Calabresse C., Bauza G., Eugène M., Calvo F. Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Cancer Res. 1996 Aug 1;56(15):3461–3467. [PubMed] [Google Scholar]
  21. Ma L. D., Marquardt D., Takemoto L., Center M. S. Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem. 1991 Mar 25;266(9):5593–5599. [PubMed] [Google Scholar]
  22. Metherall J. E., Li H., Waugh K. Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J Biol Chem. 1996 Feb 2;271(5):2634–2640. doi: 10.1074/jbc.271.5.2634. [DOI] [PubMed] [Google Scholar]
  23. Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160–7164. doi: 10.1073/pnas.87.18.7160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Petersen E. S., Kelley E. E., Modest E. J., Burns C. P. Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440. Cancer Res. 1992 Nov 15;52(22):6263–6269. [PubMed] [Google Scholar]
  25. Powis G., Seewald M. J., Gratas C., Melder D., Riebow J., Modest E. J. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res. 1992 May 15;52(10):2835–2840. [PubMed] [Google Scholar]
  26. Principe P., Coulomb H., Broquet C., Braquet P. Evaluation of combinations of antineoplastic ether phospholipids and chemotherapeutic drugs. Anticancer Drugs. 1992 Dec;3(6):577–587. doi: 10.1097/00001813-199212000-00004. [DOI] [PubMed] [Google Scholar]
  27. Principe P., Faussat-Suberville A. M., Coulomb H., Marie J. P., Braquet P. Flow cytometric monitoring of anthracycline accumulation after anti-neoplastic ether phospholipid treatment. Anticancer Drugs. 1994 Jun;5(3):329–335. doi: 10.1097/00001813-199406000-00011. [DOI] [PubMed] [Google Scholar]
  28. Ruetz S., Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 1994 Jul 1;77(7):1071–1081. doi: 10.1016/0092-8674(94)90446-4. [DOI] [PubMed] [Google Scholar]
  29. Sampson K. E., Wolf C. L., Abraham I. Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett. 1993 Jan 15;68(1):7–14. doi: 10.1016/0304-3835(93)90213-s. [DOI] [PubMed] [Google Scholar]
  30. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  31. Smit J. J., Schinkel A. H., Oude Elferink R. P., Groen A. K., Wagenaar E., van Deemter L., Mol C. A., Ottenhoff R., van der Lugt N. M., van Roon M. A. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993 Nov 5;75(3):451–462. doi: 10.1016/0092-8674(93)90380-9. [DOI] [PubMed] [Google Scholar]
  32. Thorgeirsson S. S., Silverman J. A., Gant T. W., Marino P. A. Multidrug resistance gene family and chemical carcinogens. Pharmacol Ther. 1991;49(3):283–292. doi: 10.1016/0163-7258(91)90059-u. [DOI] [PubMed] [Google Scholar]
  33. Winkelmann M., Ebeling K., Strohmeyer G., Hottenrott G., Mechl Z., Berges W., Scholten T., Westerhausen M., Schlimok G., Sterz R. Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. J Cancer Res Clin Oncol. 1992;118(6):405–407. doi: 10.1007/BF01629421. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES